Citigroup
BHVN

Citigroup’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Citigroup’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-361,076
Closed -$54.6M – 6223
2022
Q3 		$54.6M Buy
361,076
+315,276
+688% +$46.7M 0.04% 352
2022
Q2 		$6.67M Buy
45,800
+28,790
+169% +$3.68M 0.01% 1356
2022
Q1 		$2.02M Sell
17,010
-47,425
-74% -$5.91M ﹤0.01% 2344
2021
Q4 		$8.88M Buy
64,435
+5,822
+10% +$740K ﹤0.01% 1455
2021
Q3 		$8.14M Buy
58,613
+10,717
+22% +$1.34M ﹤0.01% 1522
2021
Q2 		$4.65M Sell
47,896
-19,267
-29% -$1.56M ﹤0.01% 1955
2021
Q1 		$4.59M Buy
67,163
+52,320
+352% +$4.23M ﹤0.01% 1843
2020
Q4 		$1.27M Buy
14,843
+8,580
+137% +$727K ﹤0.01% 3298
2020
Q3 		$407K Sell
6,263
-29,062
-82% -$1.9M ﹤0.01% 4033
2020
Q2 		$2.58M Sell
35,325
-2,390
-6% -$127K ﹤0.01% 2511
2020
Q1 		$1.28M Buy
37,715
+24,546
+186% +$1.12M ﹤0.01% 2918
2019
Q4 		$717K Sell
13,169
-7,804
-37% -$386K ﹤0.01% 4090
2019
Q3 		$875K Sell
20,973
-45,325
-68% -$1.91M ﹤0.01% 3791
2019
Q2 		$2.9M Buy
66,298
+59,882
+933% +$3.38M ﹤0.01% 2433
2019
Q1 		$330K Sell
6,416
-86,445
-93% -$3.73M ﹤0.01% 4614
2018
Q4 		$3.43M Buy
92,861
+26,019
+39% +$938K ﹤0.01% 2171
2018
Q3 		$2.51M Buy
66,842
+29,436
+79% +$1.08M ﹤0.01% 2526
2018
Q2 		$1.48M Buy
37,406
+37,244
+22,990% +$1.18M ﹤0.01% 2970
2018
Q1 		$4K Sell
162
-6
-4% -$179 ﹤0.01% 7281
2017
Q4 		$5K Buy
+168
New +$4.63K ﹤0.01% 7263
2017
Q3 		– Sell
-67
Closed -$2K – 7748
2017
Q2 		$2K Buy
+67
New +$1.54K ﹤0.01% 7106

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

Citigroup's BHVN Position: Q4 2022 in Review

Citigroup sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 361,076 shares — an estimated $54.6M sold.

Citigroup first reported a position in BHVN in Q2 2017 and held it in 21 quarters. The position peaked at $54.6M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Citigroup reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 361,076 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $54.6M.
  • Citigroup first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 21 quarters.
  • Citigroup's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $54.6M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.